CTLA4 and neoplasm: In addition, the frequency of CD4+ICOS+ T cells was also shown to be unexpectedly elevated in non-tumor tissues during treatment with CTLA-4 antibody, causing immune-related adverse events, such as colitis, which should be improved in the future (91, 95).